EGFR-TKIs Plus Chemotherapy Demonstrated Superior Efficacy Than EGFR-TKIs Alone As First-Line Setting in Advanced NSCLC Patients with EGFR Mutation and BIM Deletion Polymorphism.
Sangtian Liu,Yayi He,Tao Jiang,Shengxiang Ren,Fei Zhou,Chao Zhao,Xuefei Li,Jie Zhang,Chunxia Su,Xiaoxia Chen,Weijing Cai,Guanghui Gao,Wei Li,Fengying Wu,Jiayu Li,Jing Zhao,Qiong Hu,Mingchuan Zhao,Caicun Zhou,Fred R. Hirsch
DOI: https://doi.org/10.1016/j.lungcan.2018.04.004
IF: 6.081
2018-01-01
Lung Cancer
Abstract:Background: Non small-cell lung cancer (NSCLC) patients with both epidermal growth factor receptor (EGFR) positive mutation and B-cell chronic lymphocytic leukemia/lymphoma-like 11 (BIM) deletion polymorphism had a poor clinical response to EGFR-tyrosine kinase inhibitors (TKIs). The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus chemotherapy versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletion polymorphism. Methods: A retrospective, non-randomized analysis was conducted. BIM deletion polymorphism was detected using polymerase chain reaction (PCR) analysis and direct sequencing of DNA from peripheral blood cells. Clinical characteristics, overall survival (OS), progress-free-survival (PFS), objective response rate (ORR) and treatment-related adverse events were compared between EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy group. Results: 65 patients were enrolled. 36 of them received EGFR-TKIs and 29 received EGFR-TKIs plus chemotherapy. EGFR-TKIs plus chemotherapy had significantly higher ORR than TKIs alone (65.5% vs. 38.9%, P = 0.046). Median PFS was significantly longer in EGFR-TKIs plus chemotherapy group than in TKIs group (7.2 vs 4.7 m; P = 0.008). Median OS was numerically longer in EGFR-TKIs plus chemotherapy group than in TKIs alone (18.5 vs 14.2 m; P = 0.107). EGFR-TKIs plus chemotherapy was associated with more grade 3 or 4 hematological toxic effects than EGFR-TKIs alone. Conclusion: EGFR-TKIs plus chemotherapy conferred a significantly higher ORR, prolonged PFS and numerically longer OS in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. Further prospective studies are needed to validate these findings.